Mounjaro Shows No Heart Protection in Diabetes Study

An American study published in The BMJ has investigated the cardiovascular effects of Mounjaro in individuals with type 2 diabetes and heart disease. The research involved nearly 53,000 participants who began treatment with either Mounjaro or sitagliptin.

Scientists monitored major adverse cardiovascular events (Mace), including heart attacks, strokes, and death from any cause, across both treatment groups. The findings indicated that Mounjaro did not demonstrate a reduction in these specific cardiovascular events.

However, the analysis did reveal a secondary benefit: Mounjaro was associated with a reduction in hospital admissions resulting from infections. Researchers found that one hospital admission was avoided for every 48 patients treated with Mounjaro.

This trial-anchored evidence from clinical practice is important for estimating the expected cardiovascular benefit of initiating tirzepatide beyond standard treatments, informing shared decision-making for patients.